oral FGFR inhibitor - Astellas Pharma Inc.

oral FGFR inhibitor

Ph. I candidate for solid tumors

opt. from previously disclosed lead

Bioorg. Med. Chem.

Astellas Pharma Inc.

ontext. ASP5878 (Astellas Pharma Inc.) is an oral pan-FGFR inhibitor. The four FGFRs have emerged as attractive targets for cancer in recent years, and we’ve covered several recently. FGFR3…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.